The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice
Emma J. Haagensen(Newcastle University), David R. Newell(Newcastle University)
Cited by 13
Related Papers
Tumour necrosis factor in man: Clinical and biological observations
|British Journal of Cancer|1987|203
Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma
|British Journal of Cancer|2016|23